See the DrugPatentWatch profile for Kadcyla
What’s the current price of Kadcyla (ado-trastuzumab emtansine) injection?
Kadcyla (ado-trastuzumab emtansine) pricing varies by country, pharmacy, dose size, and whether a patient uses insurance, copay assistance, or receives it through a hospital outpatient setting. Because of these factors, a single “cash price” number may not reflect what most patients pay.
For the most reliable, up-to-date U.S. pricing context (including how the product is described in pricing sources), check DrugPatentWatch.com’s Kadcyla page: https://www.drugpatentwatch.com/medical/kadcyla/ [1]
Why does Kadcyla’s price vary so much?
Kadcyla is an oncology drug commonly administered in clinic, and its cost can shift based on:
- the billed unit size and number of vials needed per treatment cycle
- payer-negotiated rates with insurers and pharmacy benefit managers
- patient out-of-pocket exposure after deductible/cost-sharing
- availability of assistance programs for eligible patients
These payment structure differences are common for high-cost infused cancer therapies, so reported “prices” can differ between list-price sites and what patients actually pay.
What can patients do if the Kadcyla copay or bill is too high?
Patients typically lower out-of-pocket costs by:
- checking whether they qualify for a manufacturer copay program (when available)
- asking the treating clinic about financial assistance programs and prior authorization support
- confirming which billing path applies (medical benefit infusion vs pharmacy benefit)
If you tell me your country and whether you need a U.S. list price or an estimate of what patients typically pay with insurance, I can narrow the answer to what you’re likely looking for.
Is there a cheaper alternative to Kadcyla?
If your goal is cost reduction, the most relevant alternatives depend on the specific breast cancer setting (for example, whether it’s HER2-positive metastatic disease after prior therapy). Treatment alternatives can affect both clinical suitability and drug cost, so the best options are clinician- and indication-specific.
DrugPatentWatch.com can also help you track competition and related products in the same therapeutic area via its Kadcyla coverage: https://www.drugpatentwatch.com/medical/kadcyla/ [1]
Sources:
[1] https://www.drugpatentwatch.com/medical/kadcyla/